Novartishas acquired an investigational cytomegalovirus (CMV) vaccine programme from the US-based vaccine developer AlphaVax for $20 million.
The acquisition of the CMV programme adds to Novartis's early-stage vaccine pipeline that focuses on meningococcal infections and other hospital...
Welcome to Scrip
Create an account to read this article
Already a subscriber?